

Gilead Fund Commentary

June 30, 2025

AT A GLANCE

Manager: Finny Kuruvilla, MD, PhD

Fund Objective: Seeks to provide long-term capital appreciation.

About the Fund: A diversified mutual fund representing our “best ideas” for long-term capital appreciation. Historical emphases in small- and mid-cap growth, Health Care and Information Technology.

Benchmark: Bloomberg US Mid Cap Growth Index

Morningstar Category: US Fund Mid-Cap Growth

Lipper Category: Mid-Cap Growth

Net Assets: \$2.79 billion

Inception Date: July 8, 2008

Eventide Asset Management, LLC
One International Place, Suite 4210
Boston, MA 02110
877-771-EVEN (3836)
WWW.EVENTIDEFUNDS.COM

Class I: ETILX | Class A: ETAGX | Class C: ETCGX | Class N: ETGLX

Review

In the second quarter of 2025, the Gilead Fund (Class I) achieved a 18.03% return, contrasting with the Bloomberg US Mid Cap Growth Index's 11.79%. Relative to the benchmark, the Fund demonstrated strength in the Health Care and Industrial sectors, while we noted underperformance in the Communication Services and Consumer Discretionary sectors.

Contributors

Top Five Contributors¹ (%)

Q2 2025

Company	Ticker	Sector	Average Weight	Contribution to Return	Total Return ²
Verona Pharma PLC	VRNA	Health Care	5.33	2.42	48.97
TransMedics Group Inc	TMDX	Health Care	1.92	1.31	99.18
Xometry Inc	XMTR	Information Technology	3.37	1.13	35.59
GE Vernova Inc	GEV	Industrials	1.89	1.13	73.47
Toast Inc	TOST	Financials	3.54	1.10	33.52

In the second quarter of 2025, the largest positive contributors to performance were: Verona Pharma PLC, TransMedics Group Inc, Xometry Inc, GE Vernova Inc, and Toast Inc. Verona Pharma, a developer of new therapies for severe respiratory diseases including COPD, asthma, and cystic fibrosis, saw strong returns as its ongoing launch of Ohtuvayre for COPD patients exceeded consensus expectations. TransMedics Group, provider of therapy for end-stage organ failure, benefited from first quarter results being significantly ahead of expectations, driven by market growth and continued share capture. Xometry, an AI-enabled marketplace for on-demand manufacturing, delivered improving profitability as their custom parts business accelerated amid supply chain uncertainty. GE Vernova, a company that provides energy solutions including renewable energy, power generation, and grid technologies, benefitted as power plants drove strong demand for turbines and electrical products. Toast, a company that develops cloud software to equip restaurants to thrive, maintained steady growth on pricing enhancements despite a challenging backdrop among peers.

Detractors

Top Five Detractors¹ (%)

Q2 2025

Company	Ticker	Sector	Average Weight	Contribution to Return	Total Return ²
Argenx	ARGX	Health Care	1.70	-0.12	-6.87
Remitly Global Inc	RELY	Financials	0.90	-0.17	-9.76
Axsome Therapeutics Inc	AXSM	Health Care	1.46	-0.19	-10.49
Targa Resources Corp	TRGP	Energy	1.40	-0.25	-12.66
Micron Technology Inc	MU	Information Technology	0.15	-0.27	-19.96

In the second quarter of 2025, the largest negative detractors to performance were: Argenx, Remitly Global Inc, Axsome Therapeutics Inc, Targa Resources Corp, and Micron Technology Inc. Argenx, a biotechnology company that develops therapies for autoimmune diseases, has seen its shares come under pressure despite solid fundamentals due to US reimbursement dynamics and Most Favored Nation status. Remitly Global, a remittance company providing integrated financial services, saw its shares affected by negative sentiment related to potential stablecoin competition and an evolving regulatory landscape for immigration. Axsome Therapeutics, developer of novel therapies for neurological and psychiatric diseases, faced

Performance is historical and does not guarantee future results.

Portfolio Team Outlook

The second quarter saw strong market returns for both the benchmark and the Strategy as the street appeared to shift towards a cautiously optimistic posture after Trump paused higher reciprocal tariffs on most countries following the Liberation Day selloff. This proved to be an opportunity, with mega-cap tech and the Magnificent 7 leading the large-cap indices higher. Meanwhile, Artificial Intelligence (“AI”) spending and monetization fears subsided following DeepSeek-fueled weakness in the first quarter. While smid cap underperformed on a relative basis, mid-cap growth was a particular bright spot within US equities as cyclicals outperformed defensive sectors and growth indices outperformed value indices.

The Strategy significantly outperformed the benchmark during the second quarter. Outperformance was almost entirely due to stock selection, particularly within the healthcare portion of the portfolio, which remains our team’s highest area of conviction and largest sector overweight by a wide margin. Outperformance within the sector was primarily due to a culmination of company-specific catalysts, such as positive updates regarding product launches and quarterly results from larger holdings within

the portfolio. Two examples, Verona Pharma and TransMedics Group, are highlighted in the portfolio contributors section. These are companies that should have minimal impact from tariffs. Outside of healthcare, other bright spots for the portfolio included positive allocation effects from real estate and energy as well as strong stock selection within industrials and utilities. Positive attributors were partially offset by negative effects from an underweight to communication services and weak selection within consumer discretionary.

Looking forward, we continue to focus our efforts on issues that matter the most to our portfolio companies. As the market continues to digest geopolitical and tariff-related headlines, we are becoming more convinced that company-specific fundamental updates and valuations are becoming more relevant to stock market pricing, particularly within healthcare and technology-related industries where we focus most of our research efforts for this strategy. This is evidenced by a higher degree of positive reactions to company-specific news as well as anticipation of improving capital market conditions in the most capital-dependent spaces of the market. Trough valuations in some



Finny Kuruvilla, MD, PhD
*Co-Chief Investment Officer,
Senior Portfolio Manager*

industries are another potential tailwind that could drive broader demand for these investments.

While the last three months have been strong for the smid-cap healthcare space, it is worth noting that biotech-related indices are still considerably lower from prior peaks following a 4+ year bear market starting in 2021. For example, the Biotech Industry Select index is still more than 50% below market highs. Barring a recession in the near term, it is our view that the future still remains brighter than the past for investors with a long-term focus.

The Strategy remains grounded in the belief that companies with strong competitive advantages in attractive industries run by great management teams that focus on value creation for stakeholders will generate attractive returns for our clients over the long-term.

hurdles in clinical development and the regulatory process. Targa Resources, a midstream natural gas and NGL provider in the Permian Basin, fell on expectations of lower system volumes and slowing energy production. Micron Technology, a semiconductor company specializing in memory and storage chips, underperformed amid questions surrounding tariffs, secular AI growth, and the economic cycle.

Trailing Returns³ (%)

30 Jun 2025

	YTD	3-mos	1-year	3-year ⁴	5-year ⁴	10-year ⁴	Since Inception ⁴	Inception Date
<i>Eventide Gilead Fund</i>								
Class I	8.61	18.03	13.84	9.56	5.85	9.09	13.06	02/02/2010
Class A without load	8.48	17.98	13.58	9.30	5.60	8.82	13.84	10/28/2009
Class A with 5.75% load ⁵	2.23	11.20	7.04	7.17	4.36	8.18	13.41	10/28/2009
Class C ⁵	8.07	17.76	12.70	8.48	4.79	8.00	12.97	10/28/2009
Class N	8.49	17.99	13.63	9.34	5.64	8.87	12.57	07/08/2008
<i>Benchmark</i>								
Bloomberg US Mid Cap Growth Index ⁶	4.78	11.79	16.40	15.23	11.41	10.79	10.60	07/08/2008

Performance is historical and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Investors cannot directly invest in an index, and unmanaged index returns do not reflect any fees, expenses, or sales charges. The volatility of an index may be materially different than that of the Fund, and investors should not expect the Fund to achieve the same results as a listed index. Performance data current to the most recent month-end may be obtained by calling 1-877-771-EVEN (3836).

Eventide Gilead Fund expense ratio: Class I: 1.16%; Class A: 1.41%; Class C: 2.16%; Class N: 1.36%.

1. Source: Bloomberg PORT Attribution Report. Allocation percentages are subject to change at any time, and should not be considered investment advice.
2. The total return percentage listed is impacted by the Fund's transactions and transacted price levels of the holding during the quarter.
3. The returns shown do not reflect the deduction of taxes that a shareholder would pay on fund distributions or on the redemption of fund shares. Because of ongoing market volatility, fund performance may be subject to substantial short-term changes.
4. Performance figures for periods greater than 1 year are annualized. The indices use an inception date of 07/08/2008.
5. Class A and Class C are also subject to a maximum deferred sales charge of 1.00%. This and other expenses that apply to a continued investment in the Fund are described in the Fund's prospectus.
6. The Bloomberg US Mid Cap Growth Index is a float market-cap-weighted index based on an equal-weighted combination of four factors: earnings yield, valuation, dividend yield, and growth. The constituents consist of the lower 800 in capitalization of the Bloomberg 1000 Index, which is a float market-cap-weighted benchmark of the 1000 most highly capitalized US companies.

The opinions expressed herein are those of the Fund's portfolio management team as of 06/30/2025 and are subject to change. There is no guarantee that such views are correct or that the outlook opinions will come to pass. Specific companies mentioned are for performance attribution informational purposes only and should not be construed as buy or sell advice. Reliance upon the views expressed herein is at the sole discretion of the reader. The Adviser's judgment about the quality and intrinsic value of companies may prove to be incorrect. There is no guarantee that any investment will achieve its objectives, generate positive gains, or avoid losses.

Mutual funds involve risk including the possible loss of principal. Past performance does not guarantee future results. *The Fund's ethical values screening criteria could cause it to under-perform similar funds that do not have such screening criteria. The Fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and normally have a lower trading volume than larger companies. The Fund can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. Companies in the technology industries have different risks including but not limited to products becoming obsolete, and entrance of competing products. Companies in the Industrial Sector carry various risks including, but not limited to, risk related to debt loads, intense competition, and sensitivity to economic cycles. The Fund can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The Fund can invest in private companies. Private investments include various risks including but not limited to lack of liquidity, capital commitment risk, and valuation risk. Private companies may not be financially profitable and have uncertain futures, subjecting them to additional risks.*

This information is for use with concurrent or prior delivery of a fund prospectus, which can be obtained at <https://www.eventidefunds.com/prospectus> or by calling 1-877-771-EVEN (3836). Investors should consider a Fund's investment objectives, risks, charges and expenses carefully before investing or sending money. Eventide Mutual Funds are distributed by Northern Lights Distributors, LLC, Member FINRA/SIPC, which is not affiliated with Eventide Asset Management, LLC.